Benzinga  Jan 4  Comment 
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that Joel Barrish, Ph.D., has been named the Company's Chief Scientific Officer (CSO) and Executive Vice President, effective January 4, 2016. "It is with great excitement that we...
Benzinga  Dec 6  Comment 
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced Saturday, that an upcoming oral presentation discussing the Company's novel small molecule factor D inhibitors will take place on Sunday, December 6, 2015 during the 57th Annual Meeting of...
Motley Fool  Dec 3  Comment 
A potentially best-in-class, short-duration cure for hepatitis C makes this company one worth watching in 2016.
Motley Fool  Nov 7  Comment 
An upcoming trial by Johnson & Johnson that includes a key drug from this tiny drugmaker could eventually reward investors.
Motley Fool  Nov 6  Comment 
Optimism over an ongoing mid stage hepatitis C trial is sending shares higher.
Benzinga  Oct 16  Comment 
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) has initiated treatment in a phase 2a clinical trial to evaluate the safety, pharmacokinetics and...
FierceBiotech  Sep 17  Comment 
Gilead has already made a megablockbuster fortune out of its hepatitis C cure. But the race to cure patients faster (and probably cheaper) is still on. And Achillion today posted some new data from small studies that show its NS5A inhibitor...

You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki